Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB, Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function (Genentech, Inc. GP27839).

Next Previous
X
Search
Trial Profile

A Phase IB, Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function (Genentech, Inc. GP27839).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Liver cancer; Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech

    • Most Recent Events

    • 01 Jul 2017 Results published in the Cancer Chemotherapy and Pharmacology
    • 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top